Here, we aim to further characterise the expression of DCAF1 and KSR1 in Merlin-deficient grade I meningioma (herein referred to as meningioma), and assess the therapeutic potential of targeting these proteins/pathways using the neddylation inhibitor MLN3651, and the MEK1/2 inhibitor selumetinib [20]. Here, KSR1 is linked to meningioma.